Latest database descriptions

The objective of our project is to develop, from the existing national tools, a national research infrastructure pooling the work to collect data and validate information and health events in the service of an epidemiological research program in the field of pediatric oncology addressing :
- the environnemental and genetic risk factors for childhood cancer,
- the differences in management and their social and territorial determinants,
- the iatrogenic effects of treatments,
- and more generally, the state of health in the short-, intermediate- and long-term of people experiencing childhood cancer and the determinants of their quality of life.
The project, closely connected with the pediatric oncology research of other disciplines, has, as a secondary objective, contributing to the sharing of data across disciplines.

General objective: to establish a biological resource centre (serum, DNA) for two cohorts of patients with asthma and COBP monitored over a 10 year period. Secondary objective: to discover biological markers of severity (using proteomics technology) and genetic risk factors (by genomic-based approaches) associated with the evolution of these pathologies.

1) To test the association between constitutional DNA polymorphism, environmental parameters, molecular subtype and clinical data. The inclusion of features of both the tumour and the host will facilitate the discovery of tumourigenesis mechanisms, drugable targets and diagnostic and prognostic biomarkers.
2) To provide insight into the tumour progression knowledge and to help to identify biomarkers by the sequential sampling of recurrent tumors, plasma or urine from individual patients during follow_up.
3) To validate and extend our prior results regarding the molecular subtyping of bladder cancer on a large series of tumors collected prospectively.
4) To facilitate the transfer of study results into clinical practice thanks to the size and bladder cancer representativeness of the cohort.
5) To describe treatment patterns and to assess the direct and indirect costs of bladder cancer. The cost variability will be analyzed to identify the determinants of cost. This evaluation will pave the way for cost-benefit analyses of new biomarkers developed by the consortium.
6) To structure, at the national level, an interdisciplinary bladder cancer network including epidempiologists, bioinformaticians, health economists, molecular biologists, occupational physicians, pathologists and urologists, for coordinated and synergistic research actions and to make a significant contribution to a European multinational cohort and support international studies in genomics, in particular.

Addressing the determinants of health prognosis in obese patients who benefit from bariatric surgery.